Short Interest in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Increases By 107.0%

Posted by Brenda Bartman on Jul 17th, 2026

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT – Get Free Report) was the target of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 3,245 shares, an increase of 107.0% from the June 15th total of 1,568 shares. Based on an average trading volume of 59,123 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in shares of Xtant Medical in the 2nd quarter worth approximately $26,000. Mink Brook Asset Management LLC raised its position in shares of Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after acquiring an additional 60,997 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Xtant Medical by 7.3% during the 1st quarter. Renaissance Technologies LLC now owns 987,410 shares of the medical device company’s stock valued at $551,000 after acquiring an additional 67,550 shares in the last quarter. Tradition Wealth Management LLC bought a new position in Xtant Medical during the fourth quarter worth $79,000. Finally, Wiregrass Investment Management LLC acquired a new position in Xtant Medical in the fourth quarter worth $81,000. Institutional investors own 69.33% of the company’s stock.

Xtant Medical Stock Up 1.4%

XTNT traded up $0.01 during trading on Friday, hitting $0.45. The company had a trading volume of 71,122 shares, compared to its average volume of 145,539. Xtant Medical has a 1-year low of $0.39 and a 1-year high of $0.95. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.34 and a quick ratio of 1.64. The company has a market cap of $63.00 million, a PE ratio of 44.96 and a beta of -0.16. The business has a 50-day moving average of $0.45 and a 200-day moving average of $0.54.

Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) last released its earnings results on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $20.88 million during the quarter, compared to the consensus estimate of $20.16 million. Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%.

Analyst Upgrades and Downgrades

Separately, BTIG Research reissued a “buy” rating and issued a $1.00 price target on shares of Xtant Medical in a report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $1.00.

Read Our Latest Stock Report on Xtant Medical

Xtant Medical Company Profile

(Get Free Report)

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.